Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX-212 in advanced malignancies
NCT06528249Phase 1Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Other Engineered Cells
01
Overview
Phase 1, open-label trial of WTX212A in solid tumor and hematologic malignancy (2 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Incidence of adverse events at 1 year. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
WTX212A
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT06528249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528249.